GlassScriptPhysician profile
Cal A Domingue
NPI 1437134707
$2,616.74
in general payments reported to CMS, 2019-2025
21 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $188 · 2023: $1,046 · 2024: $1,056 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,789 · Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,789.34 |
| Food and Beverage | $513.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,789.34 | 2023-2025 | Venacure 1470 Pro |
| Merck Sharp & Dohme LLC | $118.27 | 2022-2023 | Keytruda |
| Bard Peripheral Vascular, INC. | $110.95 | 2024-2025 | Venclose Maven Catheter |
| Kerecis Limited | $100.86 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Janssen Pharmaceuticals, INC | $54.96 | 2022 | |
| Medtronic, INC. | $52.60 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.04 | 2022-2023 | Lifevest |
| Boston Scientific Corporation | $38.15 | 2021-2025 | Bodyguardian |
| Silk Road Medical, INC. | $37.47 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.35 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.70 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $28.72 | 2025 | Exparel, Iovera |
| Solventum Corporation | $27.16 | 2024 | Activ.A.C. |
| Ambu INC. | $23.56 | 2024 | |
| Convatec INC. | $22.21 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $21.76 | 2021 | |
| Integra Lifesciences Corporation | $19.35 | 2023 | Tcc-Ez |
| Amgen INC. | $17.57 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.31 | 2021 | |
| Novo Nordisk INC | $14.30 | 2023 | Ozempic, Rybelsus |
| Musculoskeletal Transplant Foundation INC. | $9.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cal Domingue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.